A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Publication|Articles|June 20, 2026
Pharmacy Practice in Focus: Oncology
- June 2026
- Volume 8
- Issue 4
Radiation Recall in Modern Oncology: Evolving Triggers and Treatment
Fact checked by: Kirsty Mackay
This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.
Advertisement
Advertisement
Radiation recall phenomenon (RRP) is an acute inflammatory reaction confined to previously irradiated tissue, triggered by the subsequent administration of systemic anticancer agents, and distinct from concurrent radiosensitization. With the rapid integration of targeted therapies and immune checkpoint inhibitors (ICIs) into oncological practice, the clinical landscape of RRP has shifted, necessitating an updated, evidence-based synthesis of its pathogenesis, contemporary triggers, and optimal management strategies.
Related to this article
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.
Advertisement
Advertisement